BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12456956)

  • 1. EPO's alter ego: erythropoietin has multiple actions.
    Lappin TR; Maxwell AP; Johnston PG
    Stem Cells; 2002; 20(6):485-92. PubMed ID: 12456956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Research advances in expression and functions of erythropoietin and erythropoietin receptor in cancers].
    Li M; Lu Y; Chen XQ
    Ai Zheng; 2008 Jun; 27(6):667-72. PubMed ID: 18570746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin biology in cancer.
    Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW
    Clin Cancer Res; 2006 Jan; 12(2):332-9. PubMed ID: 16428469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
    Monnerat C; Leyvraz S
    Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To give or not to give recombinant EPO to anemia endangered cancer patients.
    Sulkowska M; Wincewicz A; Chabowska A; Kanczuga-Koda L; Szymanska M; Koda M; Witkowska E; Sulkowski S
    Prague Med Rep; 2006; 107(3):281-9. PubMed ID: 17385400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin (rHuEPO): more than just the correction of uremic anemia.
    Buemi M; Aloisi C; Cavallaro E; Corica F; Floccari F; Grasso G; Lasco A; Pettinato G; Ruello A; Sturiale A; Frisina N
    J Nephrol; 2002; 15(2):97-103. PubMed ID: 12018644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. rHuEPO and improved treatment outcomes: potential modes of action.
    Blackwell K; Gascón P; Sigounas G; Jolliffe L
    Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia of cancer: pathogenesis and treatment with recombinant erythropoietin.
    Mittelman M
    Isr J Med Sci; 1996 Dec; 32(12):1201-6. PubMed ID: 9007154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
    Desai J; Demetri GD
    Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines.
    Djulbegovic B
    Best Pract Res Clin Haematol; 2005; 18(3):455-66. PubMed ID: 15792920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cancer-related anemia.
    Badzek S; Curić Z; Krajina Z; Plestina S; Golubić-Cepulić B; Radman I
    Coll Antropol; 2008 Jun; 32(2):615-22. PubMed ID: 18756919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The blue cross blue shield assessment technology review: summary of findings.
    Bennett CL
    Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anemia in multiple myeloma.
    Ludwig H; Pohl G; Osterborg A
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
    Mannello F; Tonti GA
    Oncologist; 2008 Jul; 13(7):761-8. PubMed ID: 18596367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin in cancer: the new face of an old friend.
    Megalakaki C
    J BUON; 2008; 13(1):7-16. PubMed ID: 18404780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythropoietin: indications and measurement].
    Klein E; Georges A; Brossaud J; Bosredon Kd; Bordenave L; Corcuff JB
    Ann Biol Clin (Paris); 2009; 67(5):505-15. PubMed ID: 19789122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
    Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
    Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin and neuroprotection: a therapeutic perspective.
    Milano M; Collomp R
    J Oncol Pharm Pract; 2005 Dec; 11(4):145-9. PubMed ID: 16595066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.